Prelude Q3 net loss $19.7M; cash into 2027; JAK2/KAT6A IND timelines set

Prelude Therapeutics Inc

2025-Q3 EPS reported -$1.09 vs consensus -$0.37 ▼ miss (-192.5%)

Q3 net loss $19.7M ($0.26/sh) vs $32.3M ($0.43) YoY; cash $58.2M at Sep 30.
Received $60M upfront from Incyte for exclusive option on JAK2V617F inhibitor; cash runway into 2027.
JAK2V617F JH2 inhibitor IND filing expected Q1 2026; oral KAT6A degrader IND mid-2026.
Preclinical data for JAK2 inhibitor and mCALR DAC accepted for oral ASH Dec 2025 presentations.
Expanded AbCellera collaboration; additional license payment received in Oct 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.